BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SinoMab BioScience readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies SinoMab BioScience's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07445919-1493@assetmemo.bio
DTSTAMP:20261121T005211Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:SM17: Phase 2 readout est. (NCT07445919)
DESCRIPTION:SM17\, phase 2\, Atopic Dermatitis.\nStudy: A Clinical Study to
  Evaluate SM17 for Atopic Dermatitis\nEstimated primary completion: 25 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sm17#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07445919
URL:https://assetmemo.bio/drug/sm17#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
